| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 42 | 22.1x | 18.2x | Around median | |
Growth | 33 | 3.3% | 7.1% | Bottom tier | |
Quality | 84 | 17.5% | 4.5% | Top tier | |
Safety | 79 | 1.1x | 2.6x | Top tier | |
Capital Return | 60 | 2.91% | 2.10% | Around median | |
Momentum | 40 | -7.7% | 2.9% | Around median | |
Sentiment | 41 | 14 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
The Procter & Gamble Company operates in everyday consumer goods through a portfolio spanning hair care, skin and personal care, personal health care, baby care, home care, fabric care, feminine care, grooming, oral care, and family care. The company relies on selling value-added brands, such as Tide, Pantene, SK-II, Vicks, Mr. Clean, Charmin, and Bounty, through stores and e-commerce; e-commerce sales grew 6% and came to represent 20% of total fiscal 2026 sales. Nine of ten product categories delivered stable or growing organic sales during the year, led by mid-single-digit growth in hair care and skin and personal care, while family care declined.
In Q4 of fiscal 2026, the company reported revenue of $21.2 billion and gross profit of $10.3 billion, equivalent to a reported gross margin of approximately 48.6%, and net income of $3.0 billion, equivalent to a net margin of approximately 14.2%. Organic sales were approximately flat, with volume, pricing, and mix approximately neutral, while core earnings per share were $1.43, down 3%, and core operating margin declined 130 basis points. Personal health care and hair and skin and personal care grew at mid-single-digit rates, while home care, feminine care, family care, and oral care declined.
For fiscal 2026, revenue was $87.0 billion, gross profit was $43.7 billion, net income was $16.0 billion, and reported earnings per share were $6.62, while core earnings per share were $6.89, up 1%. Organic sales grew by more than 1%, core gross margin declined 40 basis points, and core operating margin declined 70 basis points, despite delivering $2.8 billion in pre-tax productivity improvements. The company returned more than $15 billion to shareholders, including more than $10 billion in dividends and $5 billion in share repurchases.
The average analyst target is $157.78, within a wide range of $142 to $172, with the consensus rated “Buy”; the average is below the 52-week high of $167.25, while the highest target exceeds that high. News analyses published on July 29 and 30, 2026 showed earnings multiples between 20.5 and 22.1 times, which are not low relative to guidance for 1%–3% organic growth and 0%–3% core earnings growth in fiscal 2027, so justifying the valuation depends on successful innovation and the recovery of share growth and margins. The large difference between the $142 and $172 targets underscores the divergence in expectations between the strength of cash flows and brands on one hand, and cost pressure and slow growth on the other.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
Revenue was $21.2 billion, gross profit was $10.3 billion, and net income was $3.0 billion. Organic sales were approximately flat, with volume, pricing, and mix approximately neutral. Core earnings per share were $1.43, down 3%, while core operating margin declined 130 basis points. During the quarter, the company returned $3.5 billion to shareholders, including $2.6 billion in dividends and approximately $900 million in share repurchases.
The company expects organic growth of between 1% and 3% compared with fiscal 2026. It expects core earnings-per-share growth of between 0% and 3% to a range of $6.89–$7.11, with a midpoint of $7. The outlook includes an after-tax earnings headwind of approximately $1.4 billion, or $0.56 per share, from inputs, currencies, interest, and other items. It also expects earnings per share in Q1 of fiscal 2027 to decline by 5% or more because cost pressure is concentrated in the first half.
Tide Original Liquid shifted from decline to high-single-digit growth after performance improvements while holding price steady. Tide Evo is expanding nationally, supported by a full launch during fiscal 2027, and its technology is based on more than 50 granted patents. The improved Mr. Clean Magic Eraser also lasts twice as long, and Mr. Clean captured the equivalent of 18 times its fair share of bathroom-cleaning category growth since launch. In China, baby care delivered double-digit organic growth for six consecutive quarters.
Automated analysis for informational purposes only — not investment advice.
Management expects an after-tax headwind of nearly $1 billion in fiscal 2027 from higher raw material, energy, and transportation costs and supply-chain premiums. The estimate assumes an effective average Brent crude price of $90 per barrel, with most of the impact concentrated in the first half. This is compounded by approximately $50 million from currency effects, $150 million from higher net interest expense, and $150 million from lower after-tax non-operating income. The guidance does not include significant additional cost increases, geopolitical disruptions, or widespread supply-chain disruptions.
Organic sales in Greater China grew 4% during fiscal 2026 and 4% in Q4 of fiscal 2026, despite an approximately 2% contraction in the overall Chinese market in the latest reading cited by management. The company returned to share growth in China for the first time in 15 quarters, and baby care regained the number-one position in the market. SK-II grew 8% excluding travel retail, while fabric care and feminine care shares also improved. However, management said that work was still required in Rejoice, Crest, and Olay mass skin care.
On August 4, 2026, Procter & Gamble announced a plan to acquire Thorne, a dietary supplements brand. The move expands the company's presence in wellness and personal health care, a category that delivered mid-single-digit organic growth in Q4 of fiscal 2026. Thorne could add a growth path alongside existing health brands such as Vicks, which became the number-one cough and cold brand in Latin America during fiscal 2026. The data do not include the transaction value or a specific financial impact, so its assessment depends on execution details and subsequent disclosures.
